Search
Rigel Pharmaceuticals Inc
RIGLAdd to Watchlist
29.010USD
-2.910-9.12%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
536.75MMarket Cap
1.43P/E TTM
More Details of Rigel Pharmaceuticals Inc Company
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Rigel Pharmaceuticals Inc Info
Ticker SymbolRIGL
Company nameRigel Pharmaceuticals Inc
IPO dateNov 29, 2000
CEORodriguez (Raul R)
Number of employees162
Security typeOrdinary Share
Fiscal year-endNov 29
Address- -
City- -
Stock exchangeNASDAQ OMX - NASDAQ BASIC
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolRIGL
IPO dateNov 29, 2000
CEORodriguez (Raul R)
Company Executives of Rigel Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
282.02K
+11.42%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
76.34K
+15.20%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
62.87K
+16.17%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
34.85K
+43.43%
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
--
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
282.02K
+11.42%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
76.34K
+15.20%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
62.87K
+16.17%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
34.85K
+43.43%
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
--
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.66%
State Street Investment Management (US)
5.90%
Soleus Capital Management, L.P.
5.23%
Armistice Capital LLC
4.52%
Vanguard Capital Management, LLC
4.13%
Other
72.56%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.66%
State Street Investment Management (US)
5.90%
Soleus Capital Management, L.P.
5.23%
Armistice Capital LLC
4.52%
Vanguard Capital Management, LLC
4.13%
Other
72.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.05%
Investment Advisor/Hedge Fund
28.15%
Hedge Fund
23.74%
Research Firm
3.81%
Individual Investor
3.06%
Pension Fund
0.40%
Bank and Trust
0.40%
Venture Capital
0.07%
Family Office
0.06%
Other
3.26%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
365
17.75M
95.95%
+784.72K
2025Q4
334
15.90M
87.58%
+387.68K
2025Q3
291
14.62M
80.57%
-798.43K
2025Q2
290
14.23M
79.32%
-22.43K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
1.42M
7.67%
-65.57K
-4.42%
Dec 31, 2025
State Street Investment Management (US)
1.09M
5.91%
+536.90K
+96.86%
Dec 31, 2025
Soleus Capital Management, L.P.
300.03K
1.62%
-29.98K
-9.08%
Dec 31, 2025
Armistice Capital LLC
836.00K
4.53%
+112.00K
+15.47%
Dec 31, 2025
Marshall Wace LLP
613.60K
3.32%
+12.27K
+2.04%
Dec 31, 2025
LSV Asset Management
544.28K
2.95%
+433.38K
+390.79%
Dec 31, 2025
Renaissance Technologies LLC
539.01K
2.92%
+64.80K
+13.66%
Dec 31, 2025
Goldman Sachs Asset Management, L.P.
522.31K
2.83%
+34.05K
+6.97%
Dec 31, 2025
Acadian Asset Management LLC
493.60K
2.67%
-192.11K
-28.02%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.17%
Inspire Fidelis Multi Factor ETF
0.92%
Zacks Small/Mid Cap ETF
0.88%
First Trust Dow Jones Select MicroCap Index Fund
0.87%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.81%
Janus Henderson Small Cap Growth Alpha ETF
0.71%
First Trust Active Factor Small Cap ETF
0.24%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.24%
ALPS Medical Breakthroughs ETF
0.23%
ALPS Barron's 400 ETF
0.21%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.17%
Inspire Fidelis Multi Factor ETF
Proportion0.92%
Zacks Small/Mid Cap ETF
Proportion0.88%
First Trust Dow Jones Select MicroCap Index Fund
Proportion0.87%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0.81%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0.71%
First Trust Active Factor Small Cap ETF
Proportion0.24%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.24%
ALPS Medical Breakthroughs ETF
Proportion0.23%
ALPS Barron's 400 ETF
Proportion0.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
